Publication | Open Access

Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST)

Next GenerationTumor Mutational BurdenMedicineMetronomic TherapyImmunologyPathologyImmune Checkpoint InhibitorAnalytic ValidationMolecular DiagnosticsOncologyRadiation OncologyLung Cancer